The latest guidelines for the treatment of aortic stenosis

Abstract

Transcatheter aortic valve implantation （TAVI） for aortic stenosis （AS） has rapidly become widespread in recent years, and its indications are expanding. Large-scale clinical trials in European Union （EU） and the United States （US） show that TAVI can achieve equivalent outcomes to surgical aortic valve replacement （SAVR） or TAVI might outperform SAVR even in low-risk patients. Based on these results, TAVI was approved for low-risk cases in EU and the US. The Japanese guidelines for the treatment of valvular disease in 2020 have been completely revised and TAVI for low-risk cases has been approved in 2021 in keeping with EU and the US. This article refers to current diagnostic methods, and surgical and transcatheter interventions for AS in the latest guidelines.